Par EIS Fund
“a contender to the current established growth EIS providers such as Draper, Parkwalk and MMC…” Tax Efficient Review (86/100)
Having exited 18 businesses and returning more cash to EIS investors than many better known funds, Par Equity are a leading EIS fund manager. The company has been built by investors, for investors.
Why invest?
- IRR in excess of 27% from 18 exits
- Track record of returning cash to EIS investors (£51m returned to date)
- Diversification from London and the South East based investments
- Co-investing with a large network of experienced Angel investors and savvy entrepreneurs
- Relatively swift deployment, within a target of 12 months
About the Par EIS Fund
Par Equity are well recognised in the market as being a hands-on, value-add investor. In a typical year, Par will lead 5-6 new investment opportunities, as well as supporting c. 25 follow-on transactions. In this way, Investors in the Fund benefit as Par Equity has the ability to follow its money on deals, protecting our collective investor group’s position. Furthermore, where applicable, Investor’s funds can be deployed into more mature portfolio companies, which have already received investment from the Par Investor Network and where we have a better understanding for the opportunity, as well as the risks.
The best entrepreneurs look for experienced investors with a track record in rolling up their sleeves, which is exactly what Par Equity brings to the table. The core investment team has a balance of entrepreneurs, management consultants, corporate finance professionals and technologists. Given our regional focus, the depth and breadth of the wider Investor Network around Par Equity is second to none. Par Equity is a melting pot of ideation and experience, delivering better outcomes for our portfolio companies and Investors.
Portfolio examples
International Correspondence Schools (ICS) provides wide distance learning to over 14,000 students, with a specialism in CIPD.
Today, ICS is the world’s most experienced distance learning organisation, offering over 150 flexible courses and having helped educate more than 13 million people.
This investment generated a 76x return, not including tax relief.
PathXL uses machine learning in digital pathology to improve speed and efficacy of the cancer diagnosis process.
PathXL was acquired by Philips in June 2016 providing the technology with a platform to be developed further as part of a powerful and globally recognised brand name.
The enterprise value of acquisition generated around a 2.7x cash on cash return for Par investors.
Aircraft Medical is specialist developer and producer of high-quality medical devices focused on the needs of anaesthesia and critical care professionals.
Medtronic plc (NYSE:MDT) acquired Aircraft Medical in order to support the company’s therapy innovation strategy.
The $110 million acquisition in November 2015 generated a c. 3.8x cash on cash return for Par investors.
